Results 8,561-8,580 of 24,567 for speaker:Róisín Shortall
- Written Answers — Health Services: Health Services (10 May 2012)
Róisín Shortall: As this is a service matter it has been referred to the Health Service Executive for direct reply to the Deputy.
- Written Answers — Medical Cards: Medical Cards (15 May 2012)
Róisín Shortall: As this is a service matter it has been referred to the Health Service Executive for direct reply to the Deputy.
- Written Answers — Medical Cards: Medical Cards (15 May 2012)
Róisín Shortall: As this is a service matter it has been referred to the Health Service Executive for direct reply to the Deputy.
- Written Answers — Proposed Legislation: Proposed Legislation (15 May 2012)
Róisín Shortall: I propose to take Questions Nos. 456, 477 and 478 together. The Misuse of Drugs Act 1977 and regulations made thereunder regulate and control the import, export, production, supply and possession of a range of named narcotic drugs and psychotropic substances listed in the Schedules to the Act. Substances are scheduled under the Act in accordance with Ireland's obligations under international...
- Written Answers — Medicinal Products: Medicinal Products (15 May 2012)
Róisín Shortall: The new drug for patients with progressive melanoma will now be made available. The decision is the culmination of a comprehensive technology review process within the National Cancer Control Programme which included the drug company submission, a clinical practice guideline from medical oncologists and a pharmacoeconomic analysis by the National Centre for Pharmacoeconomics.
- Written Answers — Long-Term Illness Scheme: Long-Term Illness Scheme (15 May 2012)
Róisín Shortall: I propose to take Questions Nos. 460, 467 and 469 together. The Programme for Government commits to reforming the current public health system by introducing Universal Health Insurance with equal access to care for all. As part of this, the Government is committed to introducing Universal GP Care within its first term of office. Primary legislation is required to give effect to this...
- Written Answers — Medical Cards: Medical Cards (15 May 2012)
Róisín Shortall: As this is a service matter it has been referred to the Health Service Executive for direct reply to the Deputy.
- Written Answers — Medical Cards: Medical Cards (15 May 2012)
Róisín Shortall: Medical cards are granted by the HSE on the basis of means and individual circumstances and all persons seeking a medical card must be assessed under the undue hardship principle. There are no plans to provide for the granting of medical cards to any particular group of patients with specific medical conditions. The HSE may look beyond the applicants financial situation and have regard to...
- Written Answers — Health Services: Health Services (15 May 2012)
Róisín Shortall: As this is a service matter it has been referred to the Health Service Executive for direct reply to the Deputy.
- Written Answers — Health Services: Health Services (15 May 2012)
Róisín Shortall: As this is a service matter it has been referred to the Health Service Executive for direct reply to the Deputy.
- Written Answers — Dental Services: Dental Services (15 May 2012)
Róisín Shortall: As this is a service matter it has been referred to the HSE for direct reply.
- Written Answers — Medical Cards: Medical Cards (15 May 2012)
Róisín Shortall: As this is a service matter it has been referred to the Health Service Executive for direct reply to the Deputy.
- Written Answers — Medicinal Products: Medicinal Products (15 May 2012)
Róisín Shortall: I propose to take Questions Nos. 501 to 503, inclusive, together. Pradaxa is available under the GMS Scheme, the Drug Payment Scheme and other community drugs schemes for the prevention of blood clots in adult patients who have undergone elective hip replacement surgery or elective knee replacement surgery. The HSE is assessing the availability of resources to provide for the long term...
- Written Answers — Health Service Staff: Health Service Staff (15 May 2012)
Róisín Shortall: This matter has been referred to the HSE for direct reply.
- Written Answers — Medical Cards: Medical Cards (15 May 2012)
Róisín Shortall: As this is a service matter it has been referred to the Health Service Executive for direct reply to the Deputy.
- Written Answers — Medical Cards: Medical Cards (15 May 2012)
Róisín Shortall: If a person has been refused a medical card they can lodge an appeal within 21 days. Details of the appeals process are forward to the applicant with their refusal letter. As this refusal of a medical card renewal is a service matter I have referred it to the Health Service Executive for direct reply to the Deputy.
- Medicinal Products (16 May 2012)
Róisín Shortall: The National Centre for Pharmoeconomics, NCPE, plays an important role in the assessment process for new medicines. Its findings are not, however, the sole deciding factor in the process of allocating resources for new and expensive treatments. Its report is an input into decision making, but it is not the decision. The NCPE investigates the robustness of pricing proposals and...
- Medicinal Products (16 May 2012)
Róisín Shortall: We must consider these matters in the context of the overall cost of the drugs budget. We spend about 16% of the health budget on drugs, which amounts to almost â¬2 billion. By any standard, that is a very high proportion and it is not sustainable into the future. That is why there is an onus on all of us to ensure we get better value for money in terms of drug costs. We all want to see...
- Medicinal Products (16 May 2012)
Róisín Shortall: The HSE has no role in determining the threshold. It is the role of the NCPE to consider a number of aspects with regard to how new drugs are to be assessed. I want to make it absolutely clear that there was no reduction in the threshold. I was in touch with the unit today and confirmed that since 2009 cost benefit analyses had been done on two levels, â¬45,000 per quality-adjusted life...
- Medicinal Products (16 May 2012)
Róisín Shortall: Many new drugs either above or below these levels are approved, while many others above or below them are rejected. That input from the NCPE is only one of a number of elements taken into consideration in the decision making process to approve a new drug for reimbursement.